Ustekinumab
Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found remarkable in real-wo...
Saved in:
Main Author: | Murat Borlu (Author) |
---|---|
Format: | Book |
Published: |
Galenos Publishing House,
2022-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ustekinumab: differential use in psoriasis
by: Uhlenhake EE, et al.
Published: (2011) -
Late reaction to ustekinumab infusion
by: Marina Resener Morais, et al.
Published: (2013) -
Paradoxical granulomatous reaction to ustekinumab
by: Chinemelum Obijiofor, et al.
Published: (2024) -
Efficacy and safety of ustekinumab in adolescents
by: Kellen R, et al.
Published: (2016) -
Brodalumab
by: Murat Borlu
Published: (2022)